Drug and Devices Development: Level1
Event details
| Date | 05.11.2018 › 07.11.2018 |
| Hour | 14:00 › 18:00 |
| Speaker | Gautam Maitra, (San Diego State University & AC Immune SA), - Ary Saaman, (Debiotech SA), - Claude Ammmann, (Claude Ammann Consulting SA), - (Dirk Vocke, Innovation, Merck Group), - (Kostas Kaloulis, Catalyze4Life, EPFL) |
| Location | |
| Category | Internal trainings |
Dear Colleagues,
Catalyze4Life (https://catalyze4life.epfl.ch/) is happy to announce the 1st Workshop on the Development of Drugs and Medical Devices.
Come and learn from industry experts, how your technology can be turned into a product, and additionally map your career options, by familiarizing with concepts like:
Format: 1.5h presentation followed by 1.5h case studies in groups
The content of the 3 days of the workshop is interconnected.
Schedule:
Day 1 (November 05, 2018, 14:00-17:00)
Introduction to Drug Development:
Preclinical, CMC, clinical, glossary of terms, definitions of drug, device, description of the flow of work, with explanation of the basic tasks from discovery to clinical trial submission (IND/CTA) to market, Market Authorization Application (MAA/NDA), and post-marketing surveillance (Life Cycle Management).
Day 2 (November 06, 2018, 14:00-17:00):
Clinical Trials Phase 1 to 3 and GxP Compliance
(IND/CTA)
Day 3 (November 07, 2018, 14:00-17:00):
Medical Devices:
Introduction to the medical device design and development process and regulatory clearances/approvals (EU and USA). Emphasis on devices for drug delivery.
Expectations from Participants:
1. Read background material provided
2. Stay alert
3. Show engagement
4. Have an open mind
5. Work in teams
The Instructors
Looking Forward to seeing you there,
Dr Kostas Kaloulis & Prof Bart Deplancke
Catalyze4Life (https://catalyze4life.epfl.ch/) is happy to announce the 1st Workshop on the Development of Drugs and Medical Devices.
Come and learn from industry experts, how your technology can be turned into a product, and additionally map your career options, by familiarizing with concepts like:
- Process map to product development and regulatory approval of drugs and devices
- Project simulation with case studies
- Team/groups work
- This workshop is limited to 40 participants as it shall be highly interactive. Please make
- Certificates of attendance shall be provided at the end of the course. Please make sure you follow all the course.
- Registration is compulsory at https://epfl.doodle.com/poll/rcff5aa3cv9deykp
Format: 1.5h presentation followed by 1.5h case studies in groups
The content of the 3 days of the workshop is interconnected.
Schedule:
Day 1 (November 05, 2018, 14:00-17:00)
Introduction to Drug Development:
Preclinical, CMC, clinical, glossary of terms, definitions of drug, device, description of the flow of work, with explanation of the basic tasks from discovery to clinical trial submission (IND/CTA) to market, Market Authorization Application (MAA/NDA), and post-marketing surveillance (Life Cycle Management).
Day 2 (November 06, 2018, 14:00-17:00):
Clinical Trials Phase 1 to 3 and GxP Compliance
(IND/CTA)
Day 3 (November 07, 2018, 14:00-17:00):
Medical Devices:
Introduction to the medical device design and development process and regulatory clearances/approvals (EU and USA). Emphasis on devices for drug delivery.
Expectations from Participants:
1. Read background material provided
2. Stay alert
3. Show engagement
4. Have an open mind
5. Work in teams
The Instructors
- Gautam Maitra, Instructor, Faculty Advisory Board Member, Center for Regulatory Sciences, College of Sciences, San Diego State University
- Claude Ammmann, Director Claude Ammann Consulting, Lausanne
- Ary Saaman, Director, Regulatory Affairs, Debiotech SA, Lausanne
- Dirk Vocke, Director, Innovation, Merck Group, Germany
- Kostas Kaloulis, Director, Catalyze4Life, EPFL, Switzerland
- Originators in the pharmaceutical industry contribute 60 percent of the industry’s global gross value added and 42 percent of its employment (IFPMA Report)
- The number of people employed worldwide in the pharmaceutical industry is roughly equivalent to total employment in Belgium (IFPMA Report)
- Wages and salaries per employee rose by USD 3,000 to USD 20,600 between 2006 and 2012, an increase of 16.6 percent (IFPMA Report)
- Gene therapy may disrupt the sector by offering customized, targeted patient treatment (2018 Global Life Sciences Outlook)
- About 200 3D-printed devices have been approved in the last decade that can be tailored to fit a patient’s anatomy (2018 Global Life Sciences Outlook)
Looking Forward to seeing you there,
Dr Kostas Kaloulis & Prof Bart Deplancke
Practical information
- Informed public
- Registration required